2.035

8.33% -0.185

Mersana Therapeutics Inc (MRSN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.22

Offen:

$2.23

24-Stunden-Volumen:

662.32K

Relative Volume:

0.66

Marktkapitalisierung:

$260.65M

Einnahmen:

$36.86M

Nettoeinkommen (Verlust:

$-171.67M

KGV:

-0.9975

EPS:

-2.04

Netto-Cashflow:

$-171.05M

1W Leistung:

-19.25%

1M Leistung:

-3.10%

6M Leistung:

-22.33%

1J Leistung:

+28.80%

1-Tages-Spanne:

$2.03

$2.29

1-Wochen-Bereich:

$1.98

$2.61

52-Wochen-Spanne:

$1.22

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Firmenname

Mersana Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

617-498-0020

Adresse

840 MEMORIAL DRIVE, CAMBRIDGE

Mitarbeiter

123

Twitter

@MersanaADC

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

MRSN's Discussions on Twitter

Vergleichen Sie MRSN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MRSN	2.035	260.65M	36.86M	-171.67M	-171.05M	-2.04
VRTX	449.25	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.78	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	588.46	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.73	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.50	24.89B	3.30B	-501.07M	1.03B	11.54

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-04	Hochstufung	Citigroup	Neutral → Buy
2023-07-28	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-07-27	Herabstufung	BTIG Research	Buy → Neutral
2023-07-27	Herabstufung	Citigroup	Buy → Neutral
2023-07-27	Herabstufung	Guggenheim	Buy → Neutral
2023-07-27	Herabstufung	JP Morgan	Neutral → Underweight
2023-07-27	Herabstufung	Truist	Buy → Hold
2023-07-27	Herabstufung	Wedbush	Outperform → Neutral
2023-06-16	Herabstufung	JP Morgan	Overweight → Neutral
2023-06-15	Eingeleitet	Guggenheim	Buy
2023-03-16	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-20	Eingeleitet	Citigroup	Buy
2022-11-21	Eingeleitet	Truist	Buy
2021-10-15	Fortgesetzt	BTIG Research	Buy
2021-08-30	Eingeleitet	H.C. Wainwright	Buy
2021-03-31	Eingeleitet	Credit Suisse	Neutral
2020-12-03	Eingeleitet	Stifel	Buy
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-04-29	Eingeleitet	BTIG Research	Buy
2020-01-21	Bestätigt	H.C. Wainwright	Buy
2019-03-11	Herabstufung	JP Morgan	Neutral → Underweight
2018-11-14	Hochstufung	Leerink Partners	Mkt Perform → Outperform
2018-05-08	Eingeleitet	Robert W. Baird	Outperform
2018-03-19	Herabstufung	JP Morgan	Overweight → Neutral

Alle ansehen

Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten

Nov 20, 2024

This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN

Nov 20, 2024

Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Mersana Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 19, 2024

16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World

Nov 19, 2024

Nov 18, 2024

MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World

Nov 15, 2024

MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.63 Mil (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com

Nov 14, 2024

Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com India

Nov 14, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India

Nov 14, 2024

Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com UK

Nov 14, 2024